Evidence map›Paper›PMID 36930677›Full record

ArticlePLoS biology2023

TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding.

Tian-Yeh Lim, Blake R Wilde, Mallory L Thomas, Kristin E Murphy, Jeffery M Vahrenkamp, Megan E Conway, Katherine E Varley, Jason Gertz, Donald E Ayer

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. The MYC/TXNIP axis mediates NCL-Suppressed CD8Molecular medicine (Cambridge, Mass.) · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tian-Yeh LimDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Blake R WildeDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Mallory L ThomasDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Kristin E MurphyDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Jeffery M VahrenkampDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Megan E ConwayDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Katherine E VarleyDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Jason GertzDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Donald E AyerDepartment of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, United States of America.
Huntsman Cancer Institute · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
In situ evaluation of combinatorial gene regulation in the human genomeR01HG008974 · NHGRI · UNIVERSITY OF UTAH · PI GERTZ, JASON · 2017 to 2021
$3.2M
Nutrient Sensing and Transcriptional RegulationR01CA222650 · NCI · UNIVERSITY OF UTAH · PI AYER, DONALD E · 2018 to 2022
$1.9M
New tools for studying the Myc super family in cancerR03CA234998 · NCI · UNIVERSITY OF UTAH · PI AYER, DONALD E · 2019 to 2020
$153k
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA222650NCI NIH HHS R03 CA234998NHGRI NIH HHS R01 HG008974
6 · The paper itself

Abstract

The c-Myc protooncogene places a demand on glucose uptake to drive glucose-dependent biosynthetic pathways. To meet this demand, c-Myc protein (Myc henceforth) drives the expression of glucose transporters, glycolytic enzymes, and represses the expression of thioredoxin interacting protein (TXNIP), which is a potent negative regulator of glucose uptake. A Mychigh/TXNIPlow gene signature is clinically significant as it correlates with poor clinical prognosis in triple-negative breast cancer (TNBC) but not in other subtypes of breast cancer, suggesting a functional relationship between Myc and TXNIP. To better understand how TXNIP contributes to the aggressive behavior of TNBC, we generated TXNIP null MDA-MB-231 (231:TKO) cells for our study. We show that TXNIP loss drives a transcriptional program that resembles those driven by Myc and increases global Myc genome occupancy. TXNIP loss allows Myc to invade the promoters and enhancers of target genes that are potentially relevant to cell transformation. Together, these findings suggest that TXNIP is a broad repressor of Myc genomic binding. The increase in Myc genomic binding in the 231:TKO cells expands the Myc-dependent transcriptome we identified in parental MDA-MB-231 cells. This expansion of Myc-dependent transcription following TXNIP loss occurs without an apparent increase in Myc's intrinsic capacity to activate transcription and without increasing Myc levels. Together, our findings suggest that TXNIP loss mimics Myc overexpression, connecting Myc genomic binding and transcriptional programs to the nutrient and progrowth signals that control TXNIP expression.

Indexed as

Triple Negative Breast NeoplasmsBiological TransportCarrier ProteinsGenomicsGlucoseHumansProto-Oncogene Proteins c-mycCarrier ProteinsGlucoseProto-Oncogene Proteins c-mycTXNIP protein, human

Identifiers

PMID36930677
PMCPMC10058090
OpenAlexW4327675512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.